Published in Int J Cancer on October 15, 1990
Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nucleic Acids Res (1991) 1.31
Tenascins and the importance of adhesion modulation. Cold Spring Harb Perspect Biol (2011) 1.29
Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol (1994) 1.19
Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions. Br J Cancer (1995) 0.90
Immunohistochemical expression of tenascin in normal stomach tissue, gastric carcinomas and gastric carcinoma in lymph nodes. Br J Cancer (1995) 0.88
Tenascin immunoreactivity in normal and pathological bone marrow. J Clin Pathol (1993) 0.82
Tenascin C in metastasis: A view from the invasive front. Cell Adh Migr (2015) 0.81
Tenascin-C Signaling in melanoma. Cell Adh Migr (2015) 0.75
Oncogenic response of rat skin, lungs, and bones to vinyl chloride. Cancer Res (1971) 4.39
The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol (1998) 3.65
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem (1997) 2.63
Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation (1981) 2.29
The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem (1997) 2.09
Thyroid disease classification. Lancet (2000) 2.00
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer (1991) 1.95
Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol (1997) 1.85
Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem (1998) 1.83
A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol (1989) 1.73
The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer (2000) 1.71
Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells. J Cell Biol (1987) 1.68
Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett (1988) 1.61
Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer (2001) 1.60
Differential expression of the ED sequence-containing form of cellular fibronectin in embryonic and adult human tissues. J Cell Sci (1987) 1.60
Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer (1993) 1.55
Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol (2001) 1.54
The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer (1994) 1.51
Elution of fibronectin proteolytic fragments from a hydroxyapatite chromatography column. A simple procedure for the purification of fibronectin domains. Eur J Biochem (1985) 1.51
Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res (1992) 1.47
Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res (1999) 1.46
Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol (2000) 1.44
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res (1990) 1.43
Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J Cell Biol (1995) 1.43
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 1.42
Expression of emmprin by oral squamous cell carcinoma. Int J Cancer (2000) 1.42
Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers (2002) 1.40
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer (2010) 1.38
Transformed human cells release different fibronectin variants than do normal cells. J Cell Biol (1986) 1.37
Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer (1990) 1.36
Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res (2000) 1.35
Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer (1996) 1.35
Differences in domain structure between human fibronectins isolated from plasma and from culture supernatants of normal and transformed fibroblasts. Studies with domain-specific antibodies. J Biol Chem (1985) 1.34
Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer (1992) 1.34
miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis (2012) 1.33
Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nucleic Acids Res (1991) 1.31
c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol (2001) 1.29
Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett (1990) 1.28
Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res (1984) 1.26
Fibronectin: a chromatin-associated protein? Cell (1979) 1.25
Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res (1983) 1.25
Localization of the cellular-fibronectin-specific epitope recognized by the monoclonal antibody IST-9 using fusion proteins expressed in E. coli. FEBS Lett (1987) 1.24
Changes in expression of alpha 6/beta 4 integrin heterodimer in primary and metastatic breast cancer. Br J Cancer (1992) 1.24
Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer (1994) 1.23
Fetal myofibroblast-like cells isolated from post-radiation fibrosis in human breast cancer. Int J Cancer (1991) 1.22
Changes in Ia-like antigen expression on malignant human cells. Immunogenetics (1981) 1.22
Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res (2001) 1.21
Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A (1989) 1.20
Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem (1996) 1.19
Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem (1995) 1.19
Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer (1996) 1.18
A high-affinity human antibody that targets tumoral blood vessels. Blood (1999) 1.16
Fibronectin-mediated adhesion of fibroblasts: inhibition by dermatan sulfate proteoglycan and evidence for a cryptic glycosaminoglycan-binding domain. J Cell Biol (1987) 1.16
Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer (1991) 1.16
Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res (1999) 1.15
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol (2002) 1.15
Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J (2000) 1.15
Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. Lab Invest (1995) 1.14
Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res (1999) 1.14
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol (2010) 1.14
A simplified procedure for the preparation of antibodies to serum fibronectin. J Immunol Methods (1980) 1.13
Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res (1995) 1.13
Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer (1996) 1.12
Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br J Cancer (1999) 1.12
Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer (1992) 1.11
Large-scale procedure for the purification of fibronectin domains. Anal Biochem (1986) 1.11
Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer (1999) 1.11
Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol (1999) 1.10
Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol (1998) 1.10
Tenascin distribution in articular cartilage from normal subjects and from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum (1994) 1.10
Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated alpha4beta1 and alpha4beta7 integrins. J Biol Chem (1997) 1.08
Integrin expression in cutaneous malignant melanoma: association of the alpha 3/beta 1 heterodimer with tumor progression. Int J Cancer (1993) 1.07
The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem (1995) 1.07
The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J Biol Chem (1992) 1.07